RELATIVITY-123 MSS CRC unlikely to reach primary endpoint and will be discontinued
Other trials evaluating fixed-dose combinations of nivolumab and leratorimab as treatments for other tumor types will continue. The phase 3 RELATIVITY-123 trial (NCT05328908) tested nivolumab (Opdivo) and relatlimab (Opdurag) in patients with microsatellite stable (MSS) metastatic colorectal cancer (mCRC) who had disease progression after 1 to 4 days. ) is evaluating the effectiveness of combination […]